Postherpetic Neuralgia
Postherpetic neuralgia (PHN) is the most common complication of shingles (herpes zoster) — a painful rash caused by reactivation of the varicella-zoster virus that causes chickenpox. After the shingles rash heals, approximately 10 to 18 percent of patients continue to experience nerve pain lasting three months or more — this is postherpetic neuralgia. In patients over 60, the risk rises to 20 to 30 percent, and in those over 80, it may affect more than 30 percent of shingles patients. PHN is one of the most debilitating forms of neuropathic pain, significantly impairing sleep, daily functioning, and quality of life. Fortunately, several FDA-approved treatments exist, and vaccination against shingles dramatically reduces the risk of both the initial infection and its complications.
Symptoms
- persistent burning, stabbing, or aching pain in the area of the prior shingles rash
- allodynia — severe pain from light touch, clothing contact, or even a breeze over affected skin
- hyperalgesia — exaggerated pain response to normally mildly painful stimuli
- itching that may be intense and difficult to relieve
- sensory changes — altered sensation, numbness, or tingling in the affected area
- localized skin hypersensitivity lasting months to years after rash resolution
- most commonly affects the chest, back, or face — wherever the original shingles rash occurred
Causes
- reactivation of varicella-zoster virus from sensory nerve ganglia where it has lain dormant since chickenpox
- viral inflammation and direct nerve fiber damage during acute shingles infection
- sensitization of central pain processing pathways by the acute inflammatory episode
- older age — immune decline reduces ability to contain reactivated virus
- severe acute shingles rash — more extensive or painful initial infection increases PHN risk
- delayed antiviral treatment — starting antivirals more than 72 hours after rash onset increases risk
Why It Happens
After chickenpox resolves in childhood, the varicella-zoster virus does not leave the body — it retreats to the dorsal root ganglia (clusters of sensory nerve cell bodies near the spinal cord) and lies dormant indefinitely. In most people, the immune system keeps the virus suppressed for life. In others — particularly older adults, immunocompromised individuals, and those under significant stress — immune surveillance falters and the virus reactivates, traveling down sensory nerve fibers to the skin and causing the characteristic dermatomal rash of shingles.
The acute viral inflammation damages sensory nerve fibers. In some patients, this damage triggers a cascade of central and peripheral sensitization — the neural equivalent of an alarm stuck in the ‘on’ position. The central sensitization is what drives postherpetic neuralgia: even after the virus is cleared and the rash resolves, the pain processing system in the spinal cord and brain continues to generate and amplify pain signals from the damaged area. This is why PHN pain often bears little relationship to any ongoing tissue damage — it is a disorder of the nervous system itself.
FDA-Approved Treatments
Several treatments are specifically FDA-approved for postherpetic neuralgia, which distinguishes PHN from many neuropathic pain conditions where treatments are used off-label. First-line options include gabapentin (Neurontin), pregabalin (Lyrica), lidocaine patches (Lidoderm — 5% lidocaine), and the capsaicin 8% patch (Qutenza — applied in a clinical setting, not at home).
Gabapentin and pregabalin reduce pain by modulating voltage-gated calcium channels in pain-transmitting neurons. Both are effective but require dose titration to balance pain relief against sedation, dizziness, and cognitive side effects. Lidocaine patches deliver local anesthetic to the skin surface, reducing aberrant nerve firing without systemic absorption — an excellent option for localized PHN with allodynia where skin contact is the primary trigger. The capsaicin 8% patch causes an initial intense burning during application but produces sustained pain relief in many patients for up to 3 months from a single 60-minute application in a clinic.
Second-line options include tricyclic antidepressants (amitriptyline, nortriptyline) and, for severe cases, opioid medications — though long-term opioid use for PHN is reserved for patients who have failed multiple first-line treatments.
Prevention and Vaccination
The most effective intervention for postherpetic neuralgia is preventing shingles in the first place. Shingrix (recombinant zoster vaccine, two-dose series) is over 90% effective at preventing shingles and, in those who still develop shingles despite vaccination, significantly reduces the risk and severity of PHN. The CDC recommends Shingrix for all adults 50 and older, including those who have had previous shingles or received the older Zostavax vaccine. Shingrix is currently the most effective vaccine for shingles and PHN prevention available.
For patients who develop shingles, early antiviral treatment — ideally within 72 hours of rash onset — with acyclovir, valacyclovir, or famciclovir reduces viral replication, shortens the acute illness, and reduces (though does not eliminate) the risk of PHN. If you develop the characteristic unilateral painful rash of shingles, contact your physician immediately rather than waiting to see if symptoms resolve on their own.
Related Treatments
tens-therapy
low-level-laser-therapy
Frequently Asked Questions
How long does postherpetic neuralgia last?
PHN resolves spontaneously within one year in approximately half of patients. In others, it persists for years or, in some cases, indefinitely. Older patients and those with more severe initial shingles are more likely to have prolonged PHN. Active treatment significantly improves quality of life during the course of PHN and may influence long-term outcomes. There is no reliable way to predict which patients will recover within months versus which will have years of persistent pain.
Can I get postherpetic neuralgia if I’ve had the shingles vaccine?
It is possible but much less likely. Shingrix reduces the risk of shingles by over 90%, and for the small percentage who do develop shingles despite vaccination, the illness is typically milder and the risk of PHN is dramatically lower. Even vaccinated patients who develop a mild shingles episode should still receive prompt antiviral treatment.
Is the capsaicin 8% patch safe for PHN?
Yes, with appropriate clinical supervision. The capsaicin 8% patch (Qutenza) is FDA-approved for PHN and is applied in a physician’s office or pain clinic — not at home. The 60-minute application causes an intense burning sensation, which is managed with topical anesthetic or cooling. After the treatment, many patients experience significant pain relief for 2 to 3 months from a single application. It is not appropriate for all patients and requires evaluation by a specialist to determine suitability.